TY - JOUR
T1 - Factor IX replacement in surgery and prophylaxis.
AU - Zakarija, Anaadriana
PY - 2004/6
Y1 - 2004/6
N2 - Considerations for treatment of hemophilia B patients in high-risk settings are the focus of this paper, including differences in recoveries of factor IX products and variable patient responses to replacement therapy. Data support the importance of performing individual pharmacokinetic studies in determining treatment programs for hemophilia patients-for both high-risk periods such as surgery and for prophylaxis. Other considerations in choice of plasma-derived or recombinant factor IX concentrate in high-risk and other situations include product safety, cost, and availability.
AB - Considerations for treatment of hemophilia B patients in high-risk settings are the focus of this paper, including differences in recoveries of factor IX products and variable patient responses to replacement therapy. Data support the importance of performing individual pharmacokinetic studies in determining treatment programs for hemophilia patients-for both high-risk periods such as surgery and for prophylaxis. Other considerations in choice of plasma-derived or recombinant factor IX concentrate in high-risk and other situations include product safety, cost, and availability.
UR - http://www.scopus.com/inward/record.url?scp=28744438599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28744438599&partnerID=8YFLogxK
U2 - 10.1097/00001721-200406002-00002
DO - 10.1097/00001721-200406002-00002
M3 - Review article
C2 - 15322450
AN - SCOPUS:28744438599
SN - 0957-5235
VL - 15 Suppl 2
SP - S5-7
JO - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
JF - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ER -